eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU
Telephone: +44 (0)1992 467 272
Fax: +44 (0)1992 479 292
Medical Information e-mail: medicalinformationuk@merck.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 20/11/2009
SPC Sinemet CR and Half Sinemet CR

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 20/11/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
Date of revision of text on the SPC:   03-Nov-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Minor change to the expression of the product name as follows:

From 'Sinemet CR 50/200 mg Prolonged-Release Tablets' to 'Sinemet CR 50 mg/200 mg Prolonged-Release Tablets'

From 'Half Sinemet CR 25/100 mg Prolonged-Release Tablets' to 'Half Sinemet CR 25 mg/100 mg Prolonged-Release Tablets'

 

Fromto
Updated on 31/07/2009 and displayed until 20/11/2009
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Product Acquisition
Date of revision of text on the SPC:   30-Apr-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
The marketing of the Sinemet range has been transferred to Merck Sharp & Dohme Limited as of 1 August 2009 from BMS.  Section 7 of the SPC has been updated to remove BMS as a licenced distributor.
Updated on 14/01/2009 and displayed until 31/07/2009
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
Date of revision of text on the SPC:   31-Oct-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Section 1: Product names changed to include strength and pharmaceutical form

Section 6.4: The wording of the storage statement has been harmonised across the product range

Section 8: Product names changed to include strength and pharmaceutical form

        Section 9: Product names changed to include strength and pharmaceutical form and section updated to reflect last renewal date
Updated on 07/05/2008 and displayed until 14/01/2009
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   21-Apr-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
 To update section 4.4 of the SPC to include information relating to Melanoma; consequentially the PIL has been updated
Updated on 13/04/2007 and displayed until 07/05/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
 

4.4              Special warnings and precautions for use

 

Addition of:

 

Pathological gambling, increased libido and hypersexuality have been reported in patients treated with dopamine agonists for Parkinson's disease

 

4.8              Undesirable effects

 

Addition of:

 

Patients treated with dopamine agonists for treatment of Parkinson's disease, especially at high doses, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality, generally reversible upon reduction of dose or treatment discontinuation.

 

7.       MARKETING AUTHORISATION HOLDER

 

Distributed by

 

Updated to:

Bristol-Myers Squibb Pharmaceuticals Limited,

Sanderson Road, Uxbridge UB8 1DH, UK

 

10.     DATE OF REVISION OF THE TEXT

 

Updated to:

April 2007

 

 
Updated on 19/01/2005 and displayed until 13/04/2007
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 10 (date of (partial) revision of the text
Updated on 23/10/2003 and displayed until 19/01/2005
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 13/05/2003 and displayed until 23/10/2003
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 07/02/2003 and displayed until 13/05/2003
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 (date of (partial) revision of the text
Updated on 23/07/2002 and displayed until 07/02/2003
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
  levodopa
  carbidopa